|Prethrombotic state due to hypercoagulability in patients with permanent transvenous pacemakers.|
|PMID: 9342969 Owner: NLM Status: MEDLINE|
|Venous thrombosis is a relatively usual but serious complication of permanent transvenous pacing. However, the pathogenesis has not been defined. To clarify underlying abnormalities in the coagulation-fibrinolysis system in patients with permanent transvenous pacemakers, we measured serum levels of fibrinopeptide A (FPA), thrombin-antithrombin III complexes (TATs), plasmin-alpha 2 plasmin inhibitor complexes (PICs), D-dimer (D-D), beta-thromboglobulin (beta-TG), and platelet factor 4 (PF4) in 53 patients with permanent transvenous pacemakers and 10 control subjects. The patients were divided into two groups, as follows, according to the presence of mural thrombus documented along the pacing lead(s) by digital subtraction angiography and transesophageal echocardiography: Group Th (-), patients without venous route thrombus; and Group Th (+), patients with venous route thrombus. FPA and TAT levels increased significantly even in Group Th (-), and further increased in Group Th (+) compared with control subjects (FPA: 7.5 +/- 4.9, 15.3 +/- 8.8 vs 3.0 +/- 1.4 ng/mL, respectively, P < 0.05; TAT: 2.9 +/- 1.3, 4.8 +/- 2.3 vs 1.7 +/- 0.6 ng/mL, respectively, P < 0.05). There were no differences in levels of D-D, PIG, beta-TG, and PF4 among control subjects, Group Th (-), and Group Th (+). These findings suggest that the hypercoagulable state appears in patients with permanent transvenous pacemakers, even without apparent venous thrombosis. The patients with permanent transvenous pacemakers are thought to be in the prethrombotic state even if they have no venous route thrombosis.|
|T Ito; J Tanouchi; J Kato; M Nishino; K Iwai; H Tanahashi; M Hori; Y Yamada; T Kamada|
Related Documents :
|443909 - Kma-greenfield filter placement for chronic pulmonary hypertension.
6208389 - Abnormal plasminogen: a genetically determined cause of hypercoagulability.
19801789 - Prevalence of antiphospholipid antibodies in syrian patients with thrombosis.
15596639 - Deferment of objective assessment of deep vein thrombosis and pulmonary embolism withou...
1286989 - Analysis of venous access for therapeutic plasma exchange in patients with neurological...
10392509 - Deep vein thrombosis in elderly hong kong chinese with hip fractures detected with comp...
22177369 - Kawasaki disease and henoch-schönlein purpura - 10 years' experience of childhood vasc...
12794579 - Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcera...
3856489 - Merocyanine 540 recognizes membrane abnormalities of erythrocytes in chronic myelogenou...
|Type: Comparative Study; Journal Article|
|Title: Angiology Volume: 48 ISSN: 0003-3197 ISO Abbreviation: Angiology Publication Date: 1997 Oct|
|Created Date: 1997-11-18 Completed Date: 1997-11-18 Revised Date: 2009-11-19|
Medline Journal Info:
|Nlm Unique ID: 0203706 Medline TA: Angiology Country: UNITED STATES|
|Languages: eng Pagination: 901-6 Citation Subset: IM|
|Division of Cardiology, Osaka Rosai Hospital, Japan.|
|APA/MLA Format Download EndNote Download BibTex|
Aged, 80 and over
Angiography, Digital Subtraction
Antifibrinolytic Agents / blood
Antithrombin III / analysis
Blood Coagulation / physiology*
Cardiac Pacing, Artificial / adverse effects
Fibrin Fibrinogen Degradation Products / analysis
Fibrinolysin / analysis
Fibrinolysis / physiology
Fibrinolytic Agents / blood
Fibrinopeptide A / analysis
Heart Diseases / blood, etiology, radiography, ultrasonography
Pacemaker, Artificial / adverse effects*
Peptide Hydrolases / analysis
Platelet Factor 4 / analysis
Serine Proteinase Inhibitors / blood
Thrombophlebitis / blood, etiology
Thrombosis / blood, etiology*, radiography, ultrasonography
alpha-2-Antiplasmin / analysis
beta-Thromboglobulin / analysis
|0/Antifibrinolytic Agents; 0/Fibrin Fibrinogen Degradation Products; 0/Fibrinolytic Agents; 0/Serine Proteinase Inhibitors; 0/alpha-2-Antiplasmin; 0/antithrombin III-protease complex; 0/beta-Thromboglobulin; 0/fibrin fragment D; 25422-31-5/Fibrinopeptide A; 37270-94-3/Platelet Factor 4; 9000-94-6/Antithrombin III; EC 3.4.-/Peptide Hydrolases; EC 18.104.22.168/Fibrinolysin|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Relationship between ultrasound assessment of arterial wall properties and blood pressure.
Next Document: New stenosis on proximal coronary segment after directional atherectomy. Two case reports.